What Is It?
Three compounds that activate exercise physiology without the treadmill. Each flips a different metabolic switch. Each has a fundamentally different risk profile.
How Does It Work?
Each compound is more potent than the last. MOTS-c is endogenous, gentle — your mitochondria already make it. GW-501516 is synthetic, banned — GSK terminated development after cancer in every animal species. SLU-PP-332 is bleeding edge — WADA banned it before humans tried it. All three turn mice into athletes. None has been proven to do the same in humans.
Compounds Covered
- MOTS-c (endogenous peptide) — AMPK activation, mitochondrial signaling. Gentle. Mouse data only for exogenous use.
- GW-501516 / Cardarine (synthetic) — PPAR-delta agonist. +70% endurance with exercise in mice. Terminated for cancer. Schedule 9 in Australia.
- SLU-PP-332 (synthetic) — ERR pan-agonist. Activates DDIT4 (the exercise gene). First reported 2023. Zero human trials.
Run the Numbers
Compare protocols across exercise mimetics — strength, daily totals, and stack planning. Free, no login required.
Open the Calculator →The Honest Part
- All efficacy data is preclinical (mice).
- GW-501516 has three layers of cancer evidence.
- SLU-PP-332 has zero human trials.
- MOTS-c exogenous use is unstudied in humans.
- WADA bans synthetics but mostly ignores endogenous peptides (inconsistent).
- For research purposes only.
Research Sources
Verified vendors offering this compound for research purposes. Use code ROCN10 for discounts. We may earn commissions from these links.
Track Exercise Mimetics in the App
Peptide Manager Pro tracks 100+ compounds with an interactive knowledge graph, dosing calculator, protocol tracker, and AI research chat. Veteran-owned. $4.99/mo founding rate.
Get the App →